These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 38069427)

  • 21. Prescribed Drugs and the Microbiome.
    Brusselaers N
    Gastroenterol Clin North Am; 2019 Sep; 48(3):331-342. PubMed ID: 31383274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out.
    Conti G; D'Amico F; Fabbrini M; Brigidi P; Barone M; Turroni S
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.
    Steiner HE; Gee K; Giles J; Knight H; Hurwitz BL; Karnes JH
    Pharmacotherapy; 2022 Feb; 42(2):165-176. PubMed ID: 34820870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bringing pharmacomicrobiomics to the clinic through well-designed studies.
    Steiner HE; Patterson HK; Giles JB; Karnes JH
    Clin Transl Sci; 2022 Oct; 15(10):2303-2315. PubMed ID: 35899413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial peptide production in response to gut microbiota imbalance.
    Cardoso MH; Meneguetti BT; Oliveira-Júnior NG; Macedo MLR; Franco OL
    Peptides; 2022 Nov; 157():170865. PubMed ID: 36038014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases.
    Chellappan DK; Sze Ning QL; Su Min SK; Bin SY; Chern PJ; Shi TP; Ee Mei SW; Yee TH; Qi OJ; Thangavelu L; Rajeshkumar S; Negi P; Chellian J; Wadhwa R; Gupta G; Collet T; Hansbro PM; Dua K
    Chem Biol Interact; 2019 Sep; 310():108732. PubMed ID: 31276660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut microbiome interactions with drug metabolism, efficacy, and toxicity.
    Wilson ID; Nicholson JK
    Transl Res; 2017 Jan; 179():204-222. PubMed ID: 27591027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The degree of microbiome complexity influences the epithelial response to infection.
    Mans JJ; von Lackum K; Dorsey C; Willis S; Wallet SM; Baker HV; Lamont RJ; Handfield M
    BMC Genomics; 2009 Aug; 10():380. PubMed ID: 19689803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.
    Leardini D; Venturelli F; Baccelli F; Cerasi S; Muratore E; Brigidi P; Pession A; Prete A; Masetti R
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The microbiome and gynaecological cancer development, prevention and therapy.
    Łaniewski P; Ilhan ZE; Herbst-Kralovetz MM
    Nat Rev Urol; 2020 Apr; 17(4):232-250. PubMed ID: 32071434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes.
    Saad R; Rizkallah MR; Aziz RK
    Gut Pathog; 2012 Nov; 4(1):16. PubMed ID: 23194438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.
    Scher JU; Nayak RR; Ubeda C; Turnbaugh PJ; Abramson SB
    Nat Rev Rheumatol; 2020 May; 16(5):282-292. PubMed ID: 32157196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Mycobiome: Impact on Health and Disease States.
    El-Jurdi N; Ghannoum MA
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28597821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Treatment of Persistent Viral Infections.
    Moos WH; Pinkert CA; Irwin MH; Faller DV; Kodukula K; Glavas IP; Steliou K
    Drug Dev Res; 2017 Feb; 78(1):24-36. PubMed ID: 27761936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
    Swanson HI
    Drug Metab Dispos; 2015 Oct; 43(10):1499-504. PubMed ID: 26261284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.
    Wilkinson EM; Ilhan ZE; Herbst-Kralovetz MM
    Maturitas; 2018 Jun; 112():53-63. PubMed ID: 29704918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?
    Galloway-Peña JR; Jenq RR; Shelburne SA
    Clin Cancer Res; 2017 Jul; 23(13):3263-3268. PubMed ID: 28298544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of gut microbiota on drug metabolism and toxicity.
    Li H; He J; Jia W
    Expert Opin Drug Metab Toxicol; 2016; 12(1):31-40. PubMed ID: 26569070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacomicrobiomics in Western Medicine and Traditional Chinese Medicine in Type 2 Diabetes.
    Chu N; Chan JCN; Chow E
    Front Endocrinol (Lausanne); 2022; 13():857090. PubMed ID: 35600606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut microbiota: what is its place in pharmacology?
    Tarasiuk A; Fichna J
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):921-930. PubMed ID: 31544557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.